EP0519039A1 - Derives du facteur de croissance fibroblastique chez l'homme, leurs analogues et leur procede de production - Google Patents

Derives du facteur de croissance fibroblastique chez l'homme, leurs analogues et leur procede de production

Info

Publication number
EP0519039A1
EP0519039A1 EP92902427A EP92902427A EP0519039A1 EP 0519039 A1 EP0519039 A1 EP 0519039A1 EP 92902427 A EP92902427 A EP 92902427A EP 92902427 A EP92902427 A EP 92902427A EP 0519039 A1 EP0519039 A1 EP 0519039A1
Authority
EP
European Patent Office
Prior art keywords
derivatized
fibroblast growth
growth factor
bfgf
basic fibroblast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92902427A
Other languages
German (de)
English (en)
Inventor
Gilles Cauet
Paolo Caccia
Giampaolo Nitti
Federico Bertolero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Pharmacia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL, Pharmacia SpA filed Critical Farmitalia Carlo Erba SRL
Publication of EP0519039A1 publication Critical patent/EP0519039A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to derivatives of human basic fibroblast growth factor (bFGF) and its functionally equivalent analogues, as well as to a process for their production.
  • bFGF basic fibroblast growth factor
  • Human bFGF belongs to a family of structurally related proteins which have been isolated from normal and tumour tissues.
  • the family includes acidic FGF and the proto-oncogene produces int-2, hst/ks, FGF-5, FGF-6 and
  • bFGF was originally extracted from the pituitary gland as a factor exhibiting a mitogenic activity on fibroblasts and endothelial cells (Gospodarowicz; Nature, 249, 123, 1974).
  • mitogens have been given names based either on the tissue of origin or on target cell specificity, and include, among others, cartilage-derived growth factor (CDGF) (Sullivan
  • HBGF-ß heparin-binding growth factor ß
  • Control of angiogenesis by bFGF is expecially important in reproductive tissues, where it may also control growth and differentiation of granulosa cells in the corpus luteum in preparation for either luteinisation or artresia (Gospodarowicz D., Sem. Repro. Endocr., 7 , 21-39; 1989).
  • bFGF may help to regulate other highly vascular endocrine organs such as pituitary testis, thyroid, and adrenal cortex since the protein is localised immunocytochemically in these tissues and can modulate hormone synthesis (Baird A. and Bohlen P. Fibroblast growth factors. In: Sporn MB, Roberts AB eds. Handbook of experimental pharmacology. Vol. 95/1. Peptide growth factors and their receptors I. Berlin: Springer, 1990: 369-418).
  • bFGF can find an application in accelerating wound healing (especially in deep dermal lesions) in the revascularization of ischaemic tissues, in the regeneration of damaged neural tissues, in enhancing the success of tissue transplantation and of bone graft healing.
  • the present invention relates to derivatives of human basic fibroblast growth factor (bFGF) and its functionally equivalent analogues, as well as to a process for their production.
  • Human bFGF is a single chain, non-glycosylated protein having a molecular weight of approximately 16,500 daltons which was originally reported to be present in, and was extracted from, human brain (Gimenez-Gallego, G. et al; Biochem.Biophys.
  • FEBS Letter vol. 213, p. 189, 1987 describes the production of human bFGF by cultivation of a transformant obtained by cloning cDNA of human bFGF.
  • nucleotide sequence coding for human bFGF predicts a 155 amino acid translation product, but several shorter and longer forms, differing in length at the N-terminus, have been isolated from different tissues. Even the recombinantly produced molecule often appears as a mixture of different forms due to partial proteolytic degradation at the N-terminus.
  • the common 146 amino acid sequence of human bFGF is represented by the following formula:
  • This sequence may have present an N-terminal extension including the whole or a part of the following 11 aminoacid sequence.
  • Human bFGF analogues with comparable biological activities are also included in the definition of human bFGF according to the invention.
  • An analogue may be represented by a mutein derived from the above indicated forms characterized in that its aminoacid sequence differs from the natural sequence by way of amino acid substitutions, deletions, inversions and/or additions.
  • mixtures of two or more different forms of human bFGF are to be considered as functional equivalents of the natural molecule.
  • a mixture of two different forms having a N-terminal extension of 7 and 8 aminoacid residues respectively, with respect to the natural 146 aminoacid long molecule is considered in this specification.
  • this mixture is indicated with the internal code FCE 26184 which represents a human bFGF of 153-154 amino acids, precisely an approximately 50:50 mixture of a) a 153 aminoacid molecule having the sequence of 146 aminoacids shown previously for human bFGF and a N-terminal extension of 7 aminoacids as indicated in point (iv) on page 5, and b) a 154 aminoacid molecule having the sequence of 146 aminoacids shown previously for human bFGF and a N-terminal extension of 8 aminoacids as indicated in point (iii) on page 5.
  • human basic fibroblast growth factor as used in the present patent application includes the natural proteins as well as the above indicated analogues and mixtures.
  • Natural human basic FGF contains four cysteine residues, but the number of disulfide bonds if any, is unknown.
  • cysteine containing proteins produced in bacteria often form incorrect intramolecular disulfide bonds which can inhibit biological function (see human interleukin-2; Wang et al. Science (1984) 224, 1431-1433 and human fibroblast interferon; Mark et al. Proc. Natl. Acad. Sci. (USA) (1984) 81; 5662-5666).
  • Modifications of one or more of the cysteine residues present in the native bFGF proteins may minimize incorrect disulfide bridge formation, eliminate the need for use of reducing agents to stabilize the bFGF protein, and hence reduce multimerization or incorrect disulfide bonds thereby increasing the recoverable yield of the recombinantly produced analog, increasing the uniformity of the bFGF preparation by maintaining it over time in a monomeric form, improving its shelf stability and prolonging its half life when applied to wounds.
  • Seno et al. also reports that the serine 69, 87 analog does not show any increased biological activity with respect to that of natural sequence bFGF.
  • cysteines at positions 25 and 92 of the recombinantly produced human bFGF are probably joined by an intra-molecular disulfide bond.
  • the derivatized bFGF has shown an enhanced stability and an increased resistance to multimerization in a short term (5 days) incubation assay.
  • One object of the invention is to provide a recombinant human basic fibroblast growth factor or a functionally equivalent analog thereof in which at least one of the four cysteine amino acid residues is derivatized with a derivatizing agent capable of forming a direct S-C bond with the cysteine residue.
  • an object of the present invention is to provide a recombinant human basic fibroblast growth factor or a functionally equivalent analog thereof in which the two cysteines corresponding to those present in positions 69 and 87 of the 146 aminoacid form of the natural human basic fibroblast growth factor, are derivatized with a derivatizing agent capable of forming a direct S-C bond with the cysteine residues.
  • an object of the present invention is to provide a derivatized recombinant human bFGF or a functionally equivalent analog thereof in which the two cysteines corresponding to those present in positions 69 and 87 of human bFGF are derivatized, e.g., with a substituent selected from the group consisting of (-CH 2 COOH), [-CH(COOH) (CH 2 ) x COOH], (-CH 2 CONR 3 R 4 ), (R 5 ), [-(CH 2 ) n SO- 3 ], (-CHCH 2 CONR 3 CO), [-(CH 2 ) m NR 3 R 4 ] and (-CH 2 OCOCH 2 R 5 ) wherein R 3 and R 4 are each H, [-(CH 2 ) x COOH], [CH(COOH) (CH 2 ) x COOH] or C 1 -C 6 alkyl; R 5 is C 1 -C 6 alkyl or C 1 -C 4 alkoxymethyl, n is
  • the derivatized bFGFs provided by the invention may be prepared, by known methods according to procedures commonly used in the organic chemistry, by reacting the underivatized bFGF molecule with a suitable reagent carrying the desired derivatizing moiety, e.g. among those listed hereabove.
  • a derivatized recombinant human bFGF may be obtained by a method comprising dissolving a recombinant human bFGF in water or in a buffered aqueous solution containing EDTA; adjusting the pH of said solution to a value of, e.g., about 8.0; treating said pK adjusted solution with the desired derivatizing agent; eliminating from the resulting mixture the derivatizing agent in excess by loading the said mixture on a Mono S column and extensively washing the column with a buffered solution eluting the derivatized human bFGF with a linear gradient of sodium chloride and desalting the derivatized human bFGF by passing it through a Sephadex G-25 column.
  • the employed derivatizing agent is chosen according to the kind of derivatization which it is desired to obtain.
  • the derivatizing agent is chosen, e.g., from a haloacetic acid, in particular iodoacetic acid, or a salt thereof, e.g., an alkali metal salt, especially the sodium salt thereof.
  • a corresponding haloacetamide may be used as the derivatizing agent when it is desired t.o obtain a derivatized bFGF wherein the -SH group of the cysteine residues is changed to a -S-CH 2 -CONH 2 group.
  • an alkalimetaltetrathionate, a C 1 -C 4 alkyl methanethiosulphonate or a C 1 -C 6 alkylsulfone may be derivatizing agents useful for obtaining other derivatized bFGFs among those specifically mentioned herein before.
  • a particularly preferred derivatized bFGF according to the invention is human bFGF wherein the -SH groups of the cysteines 69 and 87 are derivatized to -S-CH 2 -COOH groups.
  • CM-bFGF carboxymethylated bFGF
  • Another preferred derivatized bFGF according to the invention is human bFGF wherein the -SH groups of the cysteines 69 and 87 are derivatized to -S-CH 2 -CONH 2 .
  • the derivatized compound will be referred to herebelow as CAM-bFGF which means carboxyamidomethylated bFGF.
  • the FGFs starting compounds for the derivatives of the invention are generally obtained by recombinant DNA techniques with well known procedures such as those described in the previously mentioned International Patent Application No. PCT WO87/01728 or in the European Patent Application No. 363675.
  • the derivatized human bFGFs of the present invention are useful in the same fields of application of the natural bFGF such as in the revascularization of ischaemic tissues, in the regeneration of damaged neural tissues, in the healing of wounds, ulcers and burns or as adjunct to other therapeutic regimens, for example during transplantation.
  • the derivatized human bFGFs of the invention can be administered in the form of pharmaceutical compositions comprising one or more different forms of derivatized bFGF and one or more pharmaceutically acceptable excipients.
  • compositions may be administered by parenteral injection of phosphate buffered solution or, alternatively, as sustained release compositions of gels, pastes, microspheres and the like.
  • the pharmaceutical compositions of derivatized human bFGF may comprise pharmaceutically acceptable excipients, e.g., carriers and/or diluents.
  • the derivatized human bFGF may be administered as such or as pharmaceutically acceptable salt of pharmaceutically acceptable inorganic acids, e.g., hydrochloric, hydrobromic, sulphuric and phosphoric acid, or pharmaceutical acceptable organic acids, e.g., acetic, maleic, malic, citric, succinic and tartaric acid.
  • pharmaceutically acceptable inorganic acids e.g., hydrochloric, hydrobromic, sulphuric and phosphoric acid
  • pharmaceutical acceptable organic acids e.g., acetic, maleic, malic, citric, succinic and tartaric acid.
  • pharmaceutical compositions of the invention can be prepared with known techniques according to conventional procedures.
  • a bacteria strain E. coli type B, from the Institute Pasteur collection, was transformed with a plasmid carrying both the human gene coding for bFGF and the gene for tetracycline resistance. This transformed strain was used for the production of recombinant non-glycosylated h-bFGF (human bFGF).
  • a Master Cell Bank (W.C.B.) (79 vials stored in liquid nitrogen at -190°C) of this strain were prepared. The content of one vial of W.C.B. was used as the inoculum for the fermentation phase. The fermentation process was carried out in 10 1 fermentors filled with 4 1 of culture medium.
  • Tetracycline hydrochloride was added to the medium in order to maintain the conditions of strain selection.
  • Enrichment in pure oxygen was required during the fermentation phase in order to allow a large bacterial growth.
  • the cells were separated from the total fermentation broth by centrifugation.
  • the resulting pellet was resuspended in a sodium phosphate buffer containing sodium chloride.
  • a minimum of 3 passages through a high pressure homogenizer were necessary for efficient cell breakage.
  • the resulting cell lysate was clarified by centrifugation and the supernatant was collected for further processing.
  • the clarified supernatant was loaded on a column of Sepharose (Trade Mark) S Fast Flow (cation exchanger) and the product was eluted from this column using a gradient of increasing sodium chloride concentrations in a phosphate buffer (Trade Mark).
  • the product was further purified on a column of Heparin Sepharose 6 B by eluting with a gradient of increasing sodium chloride concentration in a phosphate buffer.
  • a buffer exchange was made on a Sephadex (Trade Mark) G25 resin to obtain the product in the bulk product buffer (Sodium phosphate -EDTA).
  • Sepharose S Fast Flow and Sephadex G25 columns were sanitized by washing with sodium hydroxide solutions.
  • a recombinantly produced protein corresponding to the natural human bFGF (146 amino acids) can be obtained, for example, following the method described in the published International
  • CM-FGF carboxymethylated bFGF
  • rhbFGF recombinant human basic Fibroblast Growth Factor 146 amino acid long form
  • CM-FGF carboxymethylated rhbFGF
  • CAM-FGF carboxyamidomethylated rhbFGF
  • CM-FGF, CAM-FGF and rhbFGF were subjected to SH titration carried out in 6M guanidine hydrochloride, 0.1 M Tris-HCl, 1.5 mM EDTA, pH 8.0 using 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) essentially according to Habeeb, A.F.S.A. 25 Methods Enzymol. 457-465 (1972).
  • the protein concentration of the different solutions of rhbFGF and its derivatives was estimated by amino acid analysis.
  • the SH titration resulted in detection of exactly 2 moles of free sulfhydryl per molecule in the case of all the derivatized molecules and 4 moles of free sulfhydryl per molecule in the case of rhbFGF. This suggested that whereas purified rhbFGF had all the four sulfhydryl groups free, CM-FGF and CAM-FGF had two free sulfhydryl groups and two derivatized cysteines.
  • peptide mapping was attempeted with two different proteolytic treatment, i.e. with trypsin and V8 Staphilococcus aureus protease.
  • peptide mapping was also performed under the same conditions on the native recombinant bFGF and on a derivative with all cysteine alkylated, pyridylethylated-CM-FGF
  • Trypsin digestion - bFGF samples were digested with TPCK treated trypsin at 37°C for 24 hours in 0.1 M ammonium bicarbonate at pH 8 with an enzyme-to-substrate ratio of 1:50 (w/w).
  • RP-HPLC - Digests were subjected to reversed-phase HPLC on a ⁇ Bondapak C18 column (Waters; 3.9 ⁇ 300 mm, 10 ⁇ ) eluted with a linear gradient from 5% to 65% of acetonitrils in 0.1% TFA in 60 or 90 min., at a flow rate of 1 ml/min.
  • Samples were injected by means of a Water Wisp autosampler: for further analysis fractions were manually collected, monitoring at 220 nm.
  • N-terminal sequence analysis Automated N-terminal sequence analysis was performed on a gas-phase sequencer mod. 470A or on a pulsed liquid phase sequencer mod 477A (Applied Biosystems) equipped with an on-line HPLC PTH-Analyzer mod. 120A (Applied Biosystems).
  • Trypsin mapping was tried as a first attempt to identify which cysteine residues are alkylated in the CM-FGF; on the basis of the primary structure of bFGF and trypsin specificity, three cysteine containing peptides are expected, namely 23-26 (Cys 25), 67-72 (Cys 69), 87-97 (Cys 87 and 92). Comparison of tryptic maps of CM-FGF vs. bFGF (Fig.
  • CM-FGF V8 protease digestion of CM-FGF vs. PE-CM-FGF (Fig. 2) allows straight identification of CM-Cys 69 in peptide 60-78, CM-Cys 87 in peptide 79-91 and PE-Cys 92 in peptide 92-96, while Cys 25 was proved to be susceptible to pyridylethylation only by direct
  • CM-FGF and rhbFGF at a concentration of 300 ⁇ g/ml in 25 mM phosphate buffer pH 7.5/0.125 M NaCl/0.1 mM EDTA was filtered through a Millipore sterile Millex-0.22 ⁇ filter unit and incubated at 25°C and 4°C.
  • FIG. 4 shows the same after three weeks incubation time at
  • CM-FGF and rhbFGF were both incubated at 37°C at a protein concentration of 300, 100, 50 and 25 ⁇ g/ml in 25 mM phosphate buffer pH 7.5 / 0.125 M NaCl / 0.1 mM EDTA in sterile conditions. After 1,2 and 7 days an aliquot of each solution was taken and subjected to an HPLC analysis using the same conditions described above.
  • Figure 5 shows the percent of the initial amount of CM-FGF vs. rhbFGF at different times for each protein concentration in the incubation buffer. The actual amount of rhbFGF and CM-FGF after 7 days at the different concentrations compared with the initial quantity of protein was:
  • rhbFGF measured in solution after 7 days incubation time at 37°C was only 5% of the total initial amount whereas 72.3% of CM-FGF was recovered at that time.
  • the sample of rhbFGF and CM-FGF used to evaluate the stability by HPLC were also assayed for their biological activity according to the in vitro mitogsnesis assay in 3T3 cells reported below.
  • the biological activity data paralleled the analytical data reported in the above table, confirming a considerable loss of activity for rhbFGF and much less so for CM-FGF. Due to the increased stability of carboxymethylated bFGF even at very low concentrations new formulative and therapeutic approaches could be seen. The likely higher bioavaliability of the product in vivo could lead to a lower therapeutic dose associated to decreased side effects.
  • FGF was originally described as a mitogen in 3T3 fibroblasts and subsequently was found to be a potent mitogen for other cells, including endothelial cells. For this reasons, in order to compare the mitogenic activity of CM-FGF vs. rhbFGF, they were assayed in Balb/c 3T3 fibroblasts, and in bovine aortic endothelial cells. Further, an in vitro competitive receptor binding assay on isolated cells was used to evaluate the affinity of the modified bFGF molecule i.e. CM-FGF as compared to the parent intact recombinant bFGF.
  • CM-FGF modified bFGF molecule
  • A31-1-1 cells a cell line established from Balb/c mouse embryos, were grown in Eagle's minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml of penicillin and 100 ⁇ g/ml of streptomycin.
  • MEM Eagle's minimal essential medium
  • FBS fetal bovine serum
  • the mitogenic activity was determined by measuring the incorporation of 3 H-thymidine into cellular DNA.
  • subconfluent cultures were detached by trypsinization and plated (1 ⁇ 10 4 cells in 200 ⁇ l/well) in 96 well micro-titre plates.
  • the "seeding medium” contained a reduced amount (3% v/v) of fetal bovine serum (FBS).
  • FBS fetal bovine serum
  • the cultures were incubated at 37°C, 5% CO 2 and 95% humidified atmosphere; 22 h later, the "seeding medium” was replaced with a "starvation medium” consisting of Eagle's MEM with 0.1% (v/v) FBS and incubation was continued for a second period of 22 hrs.
  • the cells were washed once with phosphate buffered saline (PBS) and subsequently refed with fresh serum-free "exposure medium” consisting of MEM supplemented with 0.1% bovine serum albumin (BSA) in which samples were diluted at the concentrations to be tested.
  • PBS phosphate buffered saline
  • exposure medium consisting of MEM supplemented with 0.1% bovine serum albumin (BSA) in which samples were diluted at the concentrations to be tested.
  • Balb/3T3 cells were labelled by addition of 3 H-thymidine (sp.ac. 20 Ci/mmol; 0.25 ⁇ Ci/well) and the exposure was continued for an additional 16 hrs. Thereafter the medium was removed, and cells in each well were washed 2 times with Ca ++ /Mg ++ - free PBS. Then PBS containing 0.02% EDTA and 0.25% trypsin (100 ⁇ l/weil) were added and the plates were incubated for 10' to achieve complete detachment of the cultures. Cells in each well were collected on glass-fiber filters using the cell-harvester and wells were washed 15 times with distilled water to assure both adequate cell-lysis and washing to remove the unbound 3 H-thymidine.
  • 3 H-thymidine sp.ac. 20 Ci/mmol; 0.25 ⁇ Ci/well
  • Airdried filters were placed into vials containing 4 ml of liquid scintillation cocktail.
  • the radioactivity retained on the filters was determined in a scintillation counter.
  • DMEM Dulbecco's modified Eagle's medium
  • antibiotics penicillin 100 U/ml, streptomycin 100 ⁇ g/ml
  • FBS 13% v/v
  • the cells were allowed to attach for a period of 6 hours. Thereafter, the medium was removed and the samples diluted at desired concentration into experimental media, (DMEM supplemented with 0.5% FBS, 0.1% BSA) were added to cells.
  • the cultures were incubated for 3 days at which time they were fixed with 10% phosphate buffered formalin and stained with 0.5% crystal violet for 10'. After staining, wells were thoroughly washed to remove unincorporated stain. Methanol (95% v/v; 100 ⁇ l/well) was added to each well and incubated for 20' to extract the dye retained by the cultures to an extent proportional to the number of cells grown/well.
  • Confluent BHK cells were seeded in 24 well plates in DMEM supplemented with 10% FBS supplemented with antibiotics (penicillin 100 U/ml, streptomycin 100 ⁇ g/ml).
  • Binding was carried out at 4°C for 3 hours, then the cells were washed twice with cold Ca ++ /Mg ++ free PBS, and twice with 2M NaCl pH 7.5, The cell-bound radioactivity was collected with 0.5 N NaOH, transferred into vials and measured by gamma-counting.
  • Japan equilibrated in 25 mM phosphate buffer pH 7.5 and eluted with a linear gradient (0-2 M) of NaCl in the same buffer at a flow rate of 1 ml/min.
  • Affinity of each sample to heparin was referred to the molarity of NaCl required to elute the particular protein from the column, as estimated by conductivity.
  • CM-FGF CM-FGF as compared to rhb-FGF was studied in a proliferation assay with BAE cells.
  • CM-FGF is approximately 25 fold more potent as the parent rhb-FGF.
  • CM-bFGF and rhbFGF were found to have similar affinities for immobilized heparin, both eluting at

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Facteurs de base recombinés de croissance fibroblastique chez l'homme, ou leurs analogues fonctionnellement équivalents, dans lesquels au moins un des quatre restes cystéines des aminoacides est dérivé. Normalement, les deux cystéines correspondant à celles présentes dans les positions 69 et 87 de la forme aminoacide 146 du facteur naturel de croissance fibroblastique chez l'homme sont dérivées par des fractions telles que -CH2COOH ou -CH2CONH2. Ces facteurs de base recombinés et dérivés de croissance fibroblastique chez l'homme peuvent servir à la cicatrisation des blessures, des ulcères et des brûlures, à la régénération du tissu nerveux abîmé, à faciliter les greffes tissulaires, à consolider les greffes osseuses, ou à revasculariser le tissu ischémique.
EP92902427A 1991-01-09 1992-01-09 Derives du facteur de croissance fibroblastique chez l'homme, leurs analogues et leur procede de production Withdrawn EP0519039A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100381A GB9100381D0 (en) 1991-01-09 1991-01-09 Human bfgf derivatives,their analogs and process for their production
GB9100381 1991-01-09

Publications (1)

Publication Number Publication Date
EP0519039A1 true EP0519039A1 (fr) 1992-12-23

Family

ID=10688136

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92902427A Withdrawn EP0519039A1 (fr) 1991-01-09 1992-01-09 Derives du facteur de croissance fibroblastique chez l'homme, leurs analogues et leur procede de production
EP92100257A Withdrawn EP0494664A1 (fr) 1991-01-09 1992-01-09 Dérivés du bFGF humain, leurs analogues et procédé pour leur production

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP92100257A Withdrawn EP0494664A1 (fr) 1991-01-09 1992-01-09 Dérivés du bFGF humain, leurs analogues et procédé pour leur production

Country Status (9)

Country Link
EP (2) EP0519039A1 (fr)
AU (1) AU1156992A (fr)
FI (1) FI923998A (fr)
GB (1) GB9100381D0 (fr)
IE (1) IE920054A1 (fr)
IL (1) IL100593A0 (fr)
MX (1) MX9200040A (fr)
WO (1) WO1992012245A1 (fr)
ZA (1) ZA92112B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206354A (en) * 1990-11-23 1993-04-27 American Cyanamid Company Dna sequence encoding active fragment of fibroblast growth factor, hbf-2
JP6429237B2 (ja) * 2015-04-14 2018-11-28 国立大学法人京都大学 免疫寛容部位形成剤及び免疫抑制性細胞の誘引剤
KR101891678B1 (ko) * 2016-07-21 2018-08-27 (주)피앤피바이오팜 변형된 n-말단 아미노산 부위를 가지는 고안정성 섬유아세포 성장인자 변이체 및 그의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824936A (en) * 1987-05-06 1989-04-25 Rorer Pharmaceutical Corporation (19-Alanine) calcitonin
KR890701607A (ko) * 1987-11-24 1989-12-21 원본미기재 섬유아세포 성장 인자의 유사체
EP0355460B1 (fr) * 1988-08-24 2000-12-27 American Cyanamid Company Stabilisation de somatotropines par modification du résidu cystéine en utilisant un site de mutagénèse dirigée ou par modification chimique
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9212245A1 *

Also Published As

Publication number Publication date
AU1156992A (en) 1992-08-17
EP0494664A1 (fr) 1992-07-15
WO1992012245A1 (fr) 1992-07-23
GB9100381D0 (en) 1991-02-20
IE920054A1 (en) 1992-07-15
FI923998A0 (fi) 1992-09-07
MX9200040A (es) 1992-12-01
FI923998A (fi) 1992-09-07
IL100593A0 (en) 1992-09-06
ZA92112B (en) 1992-10-28

Similar Documents

Publication Publication Date Title
Esch et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF.
Böhlen et al. Acidic fibroblast growth factor (FGF) from bovine brain: amino‐terminal sequence and comparison with basic FGF.
Gospodarowicz et al. Fibroblast growth factor in the human placenta
JP3332085B2 (ja) 改良型の塩基性線維芽細胞増殖因子
EP0399816B1 (fr) Purification et caractérisation d'un facteur de croissance dérivé du rétinoblastane
JP3205578B2 (ja) キメラ繊維芽細胞成長因子
US5705477A (en) Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
AU638402B2 (en) Analogs of fibroblast growth factor
US5461034A (en) Osteogenic growth polypeptides identified from regenerating bone marrow
US5656587A (en) Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
Gautschi-Sova et al. Acidic fibroblast growth factor is present in nonneural tissue: isolation and chemical characterization from bovine kidney
JPH0665680B2 (ja) 動物組織の修復
RU2073686C1 (ru) Способ получения стабильных соматотропинов, стабильные соматотропины и композиция стабильного соматотропина
US5401832A (en) Brain derived and recombinant acidic fibroblast growth factor
AU624803B2 (en) Heparin - binding brain mitogens
Harper et al. Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor
JPH10507929A (ja) 高い安定性と生物活性をもつ酸性繊維芽細胞増殖因子の類似体
AU663067B2 (en) Analogs of acidic fibroblast growth factor having enhanced stability and biological activity
EP0494664A1 (fr) Dérivés du bFGF humain, leurs analogues et procédé pour leur production
EP0384731B1 (fr) Facteurs de croissance ostéogéniques identifiés à partir de moelle osseuse régénératrice
EP0241136A2 (fr) Facteur de croissance humaine classe 1, liant l'héparine
EP0526883B1 (fr) Protéine chondromodulin-II
WO1992008473A1 (fr) Utilisation therapeutique du facteur de croissance de fibroblaste
JPH05505403A (ja) ヒトｂＦＧＦの誘導体、その類似体及びこれらの製造方法
CA2079291A1 (fr) Activite du facteur de croissance des fibroblastes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

17P Request for examination filed

Effective date: 19921125

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FARMITALIA CARLO ERBA S.R.L.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA S.P.A.

17Q First examination report despatched

Effective date: 19960507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960918